Society for Maternal-Fetal Medicine (SMFM) Consult Series:
#38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission

Society for Maternal-Fetal Medicine (SMFM); Jodie Dionne-Odom, MD;
Alan T. N. Tita, MD, PhD; Neil S. Silverman, MD

All authors and Committee members have filed conflict of interest disclosure delineating personal, professional, and/or business interests that might be perceived as a real or potential conflict of interest in relation to this publication. Any conflicts have been resolved through a process approved by the Executive Board. The Society for Maternal-Fetal Medicine has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Between 800,000-1.4 million people in the United States and more than 240 million people worldwide are infected with hepatitis B virus (HBV). Specific to pregnancy, an estimated prevalence of 0.7-0.9% for chronic hepatitis B infection among pregnant women in the United States has been reported, with >25,000 infants at risk for chronic infection born annually to these women. Vertical transmission of HBV from infected mothers to their fetuses or newborns, either in utero or peripartum, remains a major source of perpetuating the reservoir of chronically infected individuals globally. Universal screening for hepatitis B infection during pregnancy has been recommended for many years. Identification of pregnant women with chronic HBV infection through universal screening has had a major impact in decreasing the risk of neonatal infection. The purpose of this document is to aid clinicians in counseling their patients regarding perinatal risks and management options available to pregnant women with hepatitis B infection in the absence of coinfection with HIV. We recommend the following: (1) perform routine screening during pregnancy for HBV infection with maternal HBsAg testing (grade 1A); (2) administer hepatitis B vaccine and HBV immunoglobulin within 12 hours of birth to all newborns of HBsAg-positive mothers or those with unknown or undocumented HBsAg status, regardless of whether maternal antiviral therapy has been given during the pregnancy (grade 1A); (3) In pregnant women with HBV infection, we suggest HBV viral load testing in the third trimester (grade 2B); (4) in pregnant women with HBV infection and viral load >6-8 log 10 copies/mL, HBV-targeted maternal antiviral therapy should be considered for the purpose of decreasing the risk of intrauterine fetal infection (grade 2B); (5) in pregnant women with HBV infection who are candidates for maternal antiviral therapy, we suggest tenofovir as a first-line agent (grade 2B); (6) we recommend that women with HBV infection be encouraged to breast-feed as long as the infant receives immunoprophylaxis at birth (HBV vaccination and hepatitis B immunoglobulin) (grade 1C); (7) for HBV infected women who have an indication for genetic testing, invasive testing (eg amniocentesis or chorionic villus sampling) may be offered—counseling should include the fact that the risk for maternal-fetal transmission may increase with HBV viral load >7 log 10 IU/mL (grade 2C); and (8) we suggest cesarean delivery not be performed for the sole indication for reduction of vertical HBV transmission (grade 2C).

Key words: antiviral therapy, breast-feeding, chronic hepatitis, hepatitis B, immunoprophylaxis, vertical transmission, viral load

Introduction

Obstetric providers are challenged continuously with the evaluation of the potential benefits and harms of new diagnostic and therapeutic procedures or treatments for patients (mother and fetus), often in the setting of limited high-quality data (eg, from randomized clinical trials). The purpose of this document is to aid clinicians in counseling their patients regarding the risk and management options available after a positive hepatitis B surface antigen (HBsAg) test result.

What risks and potential impact does hepatitis B infection present during pregnancy?

Between 800,000-1.4 million people in the United States and >240 million people worldwide are infected with hepatitis B virus (HBV).[1] From a global public health perspective, chronic HBV infection is the major source of hepatocellular carcinoma, leading to 50% of cases worldwide and 80% in high-endemic areas for HBV. Specific to pregnancy, an estimated prevalence of 0.7-0.9% for chronic hepatitis B infection among pregnant women in the United States has been reported,[2,3] with >25,000 infants at risk for chronic infection born annually to these women.[4]

While transmission through sexual intercourse and intravenous drug abuse are the major risk factors for acquisition of hepatitis B among adults in the

United States, perinatal transmission is responsible for up to 50% of HBV infection worldwide (Table 1). Vertical transmission of HBV from infected mothers to their fetuses or newborns, either in utero or peripartum, remains a major source of perpetuating the reservoir of chronically infected individuals globally. It has been demonstrated that prenatal risk factor—based screening alone will miss many chronic HBV infections among pregnant women, thereby missing the opportunity to interrupt perinatal transmission via established neonatal protocols.[1] For this reason, universal screening for hepatitis B infection during pregnancy at the first prenatal visit has been recommended for many years by both the American Congress of Obstetricians and Gynecologists and the US Preventative Services Task Force.[5,6]

In contrast to HBV acquisition in adulthood, which more commonly leads to acute resolved infection and immunity, perinatal/neonatal HBV is more likely to lead to chronic infection and its long-term disease risks. Chronic hepatitis B infection will develop in up to 90% of exposed neonates who do not receive appropriate immunoprophylaxis, in contrast to 10-25% of infected children and only 5-10% of exposed immunocompetent adults. Among all individuals with chronic HBV infection, regardless of the timing of infection, 20% will eventually die from complications of HBV infection including cirrhosis, endstage liver disease, and liver cancer.[1]

With the exception of the major risk of perinatal transmission (see below), data are insufficient to suggest that acute or chronic HBV infection is associated with adverse pregnancy outcomes such as preterm birth, low birth weight, or gestational diabetes. However, cirrhosis due to chronic HBV may be associated with increased maternal and perinatal death, gestational hypertension, abruption, preterm birth, and fetal growth restriction.[7-13]

How are HBV-infected pregnant women identified and what have been traditional approaches to their pregnancies?

Identification of pregnant women with chronic HBV infection through

---

TABLE 1
Risk factors for hepatitis B infection

Multiple sexual partners

Intravenous drug use

Household or sexual contacts of HBV carriers

Infants born to HBV-infected women

Patients and staff who work or live in an institutional setting

Hemodialysis patients

Health care workers with contact with patient blood

Persons born in countries with high HBV seroprevalence

HBV, hepatitis B virus.

SMFM. Hepatitis B in pregnancy screening. Am J Obstet Gynecol 2016.

---

universal screening has had a major impact in decreasing the risk of neonatal infection. Recent data demonstrate that 95% of pregnant women are currently screened prior to delivery for evidence of chronic HBV infection, with rates of perinatal transmission decreasing significantly over the past 2 decades.[14]

The presence of HBsAg in maternal blood more commonly represents chronic infection than acute infection. While some adults will be identified because of symptomatic illness, the vast majority of chronically infected adults are asymptomatic. The diagnosis of the chronic carrier state is confirmed with persistence of HBsAg and the absence of hepatitis B surface antibody (HBsAb), which is a neutralizing antibody that can be detected after HBV infection has been cleared. HBsAb and HBsAg essentially do not exist together. HBsAb is also detected after successful immunization with the HBV vaccine. **Therefore, we suggest performing routine screening during pregnancy for HBV infection with maternal HBsAg testing (GRADE 1A).** Hepatitis B core antibody, on the other hand, develops in the setting of natural infection, never from immunization, and persists regardless of whether the acute infection is cleared or becomes chronic (Table 2). It is emphasized strongly that pregnancy is not a contraindication to hepatitis B vaccination. Pregnant women who are identified as being at risk for HBV infection during pregnancy (eg, having >1 sex partner during the previous 6 months, been

evaluated or treated for a sexually transmitted disease, recent or current injection drug use, or having had an HBsAg-positive sex partner) should be vaccinated.

The most common risk for perinatal HBV infection occurs when the infant comes into contact with infected vaginal blood and secretions at the time of delivery. Invasive procedures during labor and delivery (including internal monitors, episiotomy, and operative vaginal delivery) may theoretically increase the risk of transmission. However, the availability of neonatal HBV immunoprophylaxis is thought to ameliorate these risks, and current opinions do not support altering regular obstetric practices. Elective cesarean delivery has also been discussed as one way to reduce vertical transmission, but it is not recommended since available data are conflicting and of poor quality.[15] **We suggest cesarean delivery not be performed for the sole indication for reduction of vertical HBV transmission (GRADE 2C).** Similarly, in the setting of neonatal HBV immunoprophylaxis, breast-feeding is not contraindicated.[16] Studies have documented no difference in rates of infection between breast-fed and formula-fed vaccinated infants born to HBV-infected women, with rates in both groups between 0-5%.[17,18] **We recommend that women with HBV infection be encouraged to breast-feed as long as the infant receives immunoprophylaxis at birth (HBV vaccination and hepatitis B immunoglobulin) (GRADE 1C).**

TABLE 2
Interpretation of hepatitis B serologic test results (from www.cdc.gov)

Interpretation of Hepatitis B Serologic Test Results

Hepatitis B serologic testing involves measurement of several hepatitis B virus (HBV)-specific antigens and antibodies. Different serologic "markers" or combinations of markers are used to identify different phases of HBV infection and to determine whether a patient has acute or chronic HBV infection, is immune to HBV as a result of prior infection or vaccination, or is susceptible to infection.

HBsAg anti-HBc anti-HBs	negative negative negative	Susceptible
HBsAg anti-HBc anti-HBs	negative positive positive	Immune due to natural infection
HBsAg anti-HBc anti-HBs	negative negative positive	Immune due to hepatitis B vaccination
HBsAg anti-HBc IgM anti-HBc anti-HBs	positive positive positive negative	Acutely infected
HBsAg anti-HBc IgM anti-HBc anti-HBs	positive positive negative negative	Chronically infected
HBsAg anti-HBc anti-HBs	negative positive negative	Interpretation unclear; four possibilities: 1. Resolved infection (most common) 2. False-positive anti-HBc, thus susceptible 3. "Low level" chronic infection 4. Resolving acute infection

Adapted from: A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. Part I: Immunization of Infants, Children, and Adolescents. MMWR 2005;54(No. RR-16).

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Disease Control and Prevention
Division of Viral Hepatitis

CDC

www.cdc.gov/hepatitis

■ **Hepatitis B surface antigen (HBsAg):**
A protein on the surface of hepatitis B virus; it can be detected in high levels in serum during acute or chronic hepatitis B virus infection. The presence of HBsAg indicates that the person is infectious. The body normally produces antibodies to HBsAg as part of the normal immune response to infection. HBsAg is the antigen used to make hepatitis B vaccine.

■ **Hepatitis B surface antibody (anti-HBs):**
The presence of anti-HBs is generally interpreted as indicating recovery and immunity from hepatitis B virus infection. Anti-HBs also develops in a person who has been successfully vaccinated against hepatitis B.

■ **Total hepatitis B core antibody (anti-HBc):**
Appears at the onset of symptoms in acute hepatitis B and persists for life. The presence of anti-HBc indicates previous or ongoing infection with hepatitis B virus in an undefined time frame.

■ **IgM antibody to hepatitis B core antigen (IgM anti-HBc):**
Positivity indicates recent infection with hepatitis B virus (≤6 mos). Its presence indicates acute infection.

http://www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf (retrieved: August 26, 2015)

SMFM. Hepatitis B in pregnancy screening. Am J Obstet Gynecol 2016.

Concerns have also been raised regarding invasive diagnostic procedures during pregnancy, such as amniocentesis, since these would occur well before the timing for immunoprophylaxis. However, the majority of reported earlier series did not demonstrate an increased risk for in utero infection after amniocentesis in women with chronic HBV infection.[19-23] These series were conducted before the routine use of HBV viral load testing as a disease marker; therefore, it may not apply to women with very high viral load as will be defined in a later section. In fact, a recent series did demonstrate an increase in risk for in utero infection after amniocentesis in women with viral titers >7 log 10 copies/mL, compared to those women with titers below that cutoff (50% vs 4%; odds ratio, 21.3; $P = .006$).[24] Such emerging data may have an impact on counseling surrounding invasive prenatal testing as data accumulate from more series using maternal HBV viral load titers. For HBV-infected women who have an indication for genetic testing, invasive testing (eg amniocentesis or chorionic villus sampling) may be offered. **Counseling should include the fact that the risk for maternal-fetal transmission may increase with HBV viral load >7 log 10 copies/mL (GRADE 2C).**

What has been the traditional approach to preventing neonatal HBV infection?

The mainstay of perinatal HBV infection prevention is a combination of active and passive immunization for exposed infants. Before the development of an HBV vaccine, HBV immunoglobulin (HBIG) alone, administered within 12 hours of delivery, was shown to be effective in providing transient passive immunity, but 25% of infants became infected through household contact by 1 year of age.[25] When the vaccine became available in the 1980s, it was subsequently shown that a combination of HBV vaccine and HBIG given within the first 12 hours after birth gave the greatest degree of durable protection, conferring long-term immunity in 85-95% of cases.[26] Immunoprophylaxis is also recommended for infants born to mothers with unknown or undocumented HBsAg status. Completion of the full 3-dose HBV vaccine series following the birth-dose vaccine is important for the newborn to gain maximal protection and is recommended for all infants irrespective of maternal HBV infection status. This approach has shown significant impact on longer-term disease outcome measures for newborns who received prophylaxis in areas that are endemic for HBV infection. In Taiwan, the institution of a universal screening and immunization program lowered the rate of chronic HBV infection among children from 10% to 1% during a 10-year period.[27] Concurrently, the rate of childhood hepatocellular carcinoma was lowered by half in the same population, from 0.7 to 0.36 per 100,000.[28] **We recommend administering hepatitis B vaccine and HBIG within 12 hours of birth to all newborns of HBsAg-positive mothers or those with unknown or undocumented HBsAg status, regardless of whether maternal antiviral therapy has been given during the pregnancy (GRADE 1A).**

How has the approach to treating HBV infection in general changed recently?

As was shown with the evolution of management of HIV-related illness, the use of HBV viral load as a predictor of disease progression and as a measure of treatment response has been a major factor regarding development of treatment models for HBV-related disease. This has resulted in development of treatment protocols for lowering and even eliminating viremia in HBV-infected adults, with evolving corollary implications for management during pregnancy.

HBV viral load has been shown to be directly related to the risk of disease progression in infected adults. In interpreting studies reporting outcomes and indications for treatment in relation to viral load, the results are inconsistently reported in relation of HBV units. Some studies provide data in the form of copies/mL, while others report in IU/mL, despite the fact that the World Health Organization has recommended that HBV DNA be expressed in terms of IU/mL. Conversion is straightforward: to convert from IU/mL to copies/mL, the IU/mL value should be multiplied by 5.6 (or the copies/mL value similarly divided).[29]

In a large prospective cohort from Taiwan, an HBV-DNA level >4 log 10 copies/mL was associated with significantly higher rates of cirrhosis, hepatocellular carcinoma, and death, independent of hepatitis B e-antigen status as a surrogate marker of viremia.[30,31] Randomized controlled trials were subsequently conducted evaluating the use of antivirals in HBV-infected adults in an attempt to lower viremia and, in turn, lower long-term disease risks. Some of the single-agent antivirals studied had been used to treat HIV infection, specifically lamivudine and tenofovir. One of the earlier trials using lamivudine demonstrated significantly less progression of hepatic fibrosis and cirrhosis over 32 months compared to placebo, but also that drug resistance developed in a high proportion of patients.[32] Subsequent trials using tenofovir and entecavir, another reverse transcriptase inhibitor, showed sustained viral suppression below detectable levels and reversal of hepatic histopathology without similar levels of resistance.[33] As a result, the American Association for the Study of Liver Diseases issued revised guidelines in 2009 for the treatment of chronic HBV infection, moving tenofovir and entecavir to first-line therapies, with lamivudine not a first-line agent due to resistance concerns.[34] More recent reports have demonstrated that in chronically infected adults, tenofovir monotherapy has maintained HBV-DNA suppression while used for up to 6 years of continuous treatment, with no evidence of tenofovir resistance, even in patients whose virus became resistant to lamivudine.[35,36] Table 3 outlines the characteristics, results, and resistance risks of currently available and studied HBV antivirals.

How has the approach to HBV in pregnancy been affected by its treatment in nonpregnant adults? What new measures now need to be considered?

While the use of HBIG and HBV vaccine neonatally has shown a dramatic impact

TABLE 3

Resistance risks and clinical issues for currently available hepatitis B virus antivirals

	Resistance data	Clinical issues
Adefovir	0—3% at 1—2 y 11—18% at 3—4 y	
Entecavir	Virologic breakthrough rare in NA-naïve patients Resistance 1—2% in naïve patients up to 5 y of treatment Resistance high (51%) in lamivudine-refractory patients	More potent than lamivudine and adefovir in vitro and in clinical trials
Lamivudine	14—32% after 1 y 60—70% after 5 y	Higher resistance with: - Longer duration of prescription - Higher baseline viremia
Telbivudine	2—5% after 1 y 11—25% after 2 y	Less resistance than lamivudine, but increases dramatically after first year
Tenofovir	No resistance after 6 y of continuous therapy, despite low rates of viral breakthrough	May be optimal first-line agent for antepartum treatment

SMFM. Hepatitis B in pregnancy screening. Am J Obstet Gynecol 2016.

in lowering rates of perinatal HBV transmission, concern persisted regarding the 5-15% of newborns who are infected despite receiving appropriate neonatal immunoprophylaxis. This subgroup has been thought to represent a cohort of newborns infected in utero but, until recently, no measures had been shown to have an impact on HBV viremia in infected individuals. The accomplishments using antivirals in adults with HBV infection led investigators to explore whether a comparable model might apply to in utero infection. Using HIV as a model, hypotheses evolved exploring the use of antivirals, particularly those with established fetal safety profiles when used in HIV-infected pregnant women, to similarly decrease the risk of intrauterine HBV infection in at-risk fetuses and newborns.

Maternal HBV-DNA level has been demonstrated to be the strongest predictor of neonatal immunoprophylaxis failure, with a lower prophylaxis effective rate directly related to a higher maternal viral load. Earlier studies showed a prophylaxis effective rate close to 100% if prelabor HBV-DNA levels were <5.5 log 10 copies/mL (equivalent to 4.8 log 10 IU/mL),[37,38] with more recent prospective studies showing a stepwise decrease in prophylaxis effective rate as HBV-DNA levels increased above 6-8 log 10 copies/mL (equivalent to 5.2-7.2 log 10 IU/mL).[39,40] Most recently, a maternal HBV-DNA level >6 log 10 copies/mL (5.2 log IU/mL) at delivery appears to be most important predictor of in utero maternal-to-child transmission (MTCT) and prophylaxis failure.[41]

Initial nonrandomized efforts to lower maternal HBV viremia in an effort to decrease MTCT rates used HBIG in variable dosing regimens during the third trimester. While these researchers demonstrated a substantial decrease in maternal viral levels, only a modest impact on MTCT rates resulted.[42-44] A subsequent larger, randomized controlled trial showed no differences in prophylaxis effective rates compared to placebo.[45] Finally, a recent Cochrane analysis showed no benefit of HBIG when used in this manner, commenting on the poor methodologic quality of the studies in general, and raising concern for the development of immune complex disease in treated mothers who received repeated dosing of immunoglobulin.[46]

As a result of the poor performance of HBIG as an intervention to lower the risk of in utero HBV infection, researchers turned to evaluating the use of HBV antivirals during pregnancy to potentially lower maternal viremia and reduce MTCT as a result. This research drew on the use of antivirals during pregnancy in HIV-infected women to effectively accomplish the same result, as well as the published results of trials using the same antivirals to treat nonpregnant HBV-infected adults. To date, small, mostly nonrandomized series have been published studying the use of lamivudine, telbivudine, entecavir, and tenofovir for this purpose. Lamivudine has been the agent used most frequently in recent trials, due to its better-established safety profile in pregnancy in the setting of maternal HIV infection, although tenofovir also has an enlarging body of registry-based data supporting its use in pregnancy.[47] A recent metaanalysis compiling data on the use of lamivudine during pregnancy for this purpose included 10 trials, although only 3 were placebo-controlled. Compared to placebo, treatment with lamivudine starting at 24-32 weeks of gestation through 4 weeks postpartum resulted in a significant 80% decrease in MTCT of HBV (odds ratio, 0.2; 0.10-0.39; *P* < .001, 95% CI).[48] Concerns are still present, however, regarding the use of lamivudine as a single agent for this purpose due to its high rate of resistance developing, reported as up to 32% after 1 year, and its potential implications for treatment of the woman after delivery should it become necessary. In addition, in one larger recent series, 62% of women treated during pregnancy with lamivudine experienced a significant postpartum flare in their liver function test (LFT) results when their medication was stopped.[39]

Other antiviral agents with much lower resistance rates have also been studied for their impact on MTCT rates for HBV, although these series have been smaller and less rigorous. The use of tenofovir, 300 mg/d, was initially reported in an observational case series of 11 women with a mean HBV viral load of 8.9 log 10 copies/mL, with medication started at 28-32 weeks of gestation and continued until delivery. The mean maternal viral load was significantly

Summary of recommendations

	Recommendations	GRADE
1	Perform routine screening during pregnancy for HBV infection with maternal HBsAg testing.	1A Strong recommendation, high-quality evidence
2	Administer hepatitis B vaccine and HBIG within 12 hours of birth to all newborns of HBsAg-positive mothers or those with unknown or undocumented HBsAg status, regardless of whether maternal antiviral therapy has been given during the pregnancy.	1A Strong recommendation, high-quality evidence
3	In pregnant women with HBV infection, we suggest HBV viral load testing in the third trimester.	2B Weak recommendation, moderate-quality evidence
4	In pregnant women with HBV infection and viral load >6-8 log 10 copies/mL, HBV-targeted maternal antiviral therapy should be considered for the purpose of decreasing the risk of intrauterine fetal infection.	2B Weak recommendation, moderate-quality evidence
5	In pregnant women with HBV infection who are candidates for maternal antiviral therapy, we suggest tenofovir as a first-line agent.	2B Weak recommendation, moderate-quality evidence
6	We recommend that women with HBV infection be encouraged to breast-feed as long as the infant receives immunoprophylaxis at birth (HBV vaccination and hepatitis B immunoglobulin).	1C Strong recommendation, low-quality evidence
7	For HBV-infected women who have an indication for genetic testing, invasive testing (eg amniocentesis or chorionic villus sampling) may be offered. Counseling should include the fact that the risk for maternal-fetal transmission may increase with HBV viral load >7 log 10 IU/mL.	2C Weak recommendation, low-quality evidence
8	We suggest cesarean delivery not be performed for the sole indication for reduction of vertical HBV transmission.	2C Weak recommendation, low-quality evidence

HBIG, HBV immunoglobulin; *HBsAg*, hepatitis B surface antigen; *HBV*, hepatitis B virus.

Guidelines

The recommendations in this document reflect the national and international guidelines related to hepatitis B infection during pregnancy.[5,6,14,22,34,56,57]

---

lowered, to 5.2 log 10 copies, with 55% of the women achieving a level <6 log 10 copies/mL. All infants were HBsAg and HBV-DNA negative at 36 weeks postdelivery, and none of the treated women experienced a postpartum LFT flare.[41] In a more recent multicenter prospective observational study, HBV antiviral therapy was given to pregnant women with elevated HBV DNA levels (>7 log 10 IU/mL) after 32 weeks of gestation. Lamivudine was used initially in the study then changed to tenofovir partway through the trial, due to emerging evidence in 2010 of increasing lamivudine resistance rates in nonpregnant adults; controls were those women who declined therapy. All newborns received recommended active and passive immunization.[49] Lamivudine and tenofovir were both associated with a reduction in vertical transmission risk (0% and 2%, respectively) compared to no antiviral therapy (20% transmission). Tenofovir compared with lamivudine was associated with a higher mean decrease in HBV viral load by delivery (3.6 vs 2.8 log 10 IU/mL) and fewer antiviral failures (delivery viral load >7 log 10 IU/mL, 3% vs 18%). Neither agent was associated with an increase in congenital abnormalities or difference in infant growth parameters at birth compared to the untreated control group.[49] In another study telbivudine was used to treat highly viremic women (viral load >6 log 10 IU/mL) from 24-32 weeks of gestation. The medication was well tolerated and the vertical transmission rate was 0%, compared to 20% in the control group who did not receive antiviral therapy.[50]

Based on these studies and others, the use of lamivudine, tenofovir, or telbivudine after 28-32 weeks of gestation for HBV-infected women with high viral load (>6-8 log 10 copies/mL) has been suggested, in addition to administration of both HBV vaccine and HBIG within 12-24 hours of birth, to minimize in utero infection and to maximize neonatal HBV prevention.[48,51]

It has also been demonstrated, in a recent study employing a decision-tree model that perinatal antiviral prophylaxis is cost-effective across a wide range of assumptions when either a positive hepatitis B e-antigen or high maternal viral load (>6-8 log 10 copies/mL) is present. In this analysis, the researchers demonstrated that single-agent anti-HBV therapy during pregnancy remained cost-saving unless the reduction in perinatal transmission was <18.5%, which is higher than shown in any antiviral study to date. In addition, this treatment arm would prevent 9.7 cases of chronic hepatitis B in newborns for each 100 women treated and save $5184 per 100 women treated.[52] Other decision-analysis model-based studies have drawn similar conclusions regarding the cost-effectiveness of single-agent anti-HBV therapy during pregnancy. In one, for every 1000 women treated with lamivudine, $337,000 was

saved, 314 quality-adjusted life-years were gained, and 21 cases of hepatocellular carcinoma and 5 liver transplants were prevented in offspring.[53]

Many pregnant women with HBV and HIV coinfection are already being treated with dually active agents—tenofovir, emtricitabine, or lamivudine—and trials showing efficacy and safety in this population are ongoing.[54] A recent analysis of antiretroviral registry data looking specifically at the fetal safety profiles of the subgroup of anti-HIV agents also effective against HBV demonstrated no increase in exposure risk. For tenofovir, for example, the registry had compiled data on a sufficient number of first-trimester exposures to detect at least a 2-fold increase risk in birth defects, with none demonstrated.[47,55] Finally, regarding breastfeeding, the use of lamivudine and tenofovir in the postpartum period is not currently recommended solely for HBV prevention until additional data are available.[55] Most published study protocols, however, have stopped the maternal HBV therapy at the time of delivery, so this may not be a significant management issue.

No guidelines currently exist in the United States regarding the use of antiviral therapy against HBV during pregnancy specifically for the goal of decreasing the risk of in utero infection and vertical transmission. However, it is being offered increasingly in centers where practitioners already have experience with the use of similar antivirals for the management of HIV-infected pregnant women. Precedent for establishment of universal guidelines exists already in Europe, where both the European Association for the Study of the Liver and the United Kingdom's National Institute for Health and Care Excellence have published such guidelines in 2012 and 2013, respectively.[56-58] Both agencies currently advocate discussion of antiviral therapy with HBV-infected pregnant women with viral loads >6-7 log 10 IU/mL (6.7-7.7 log 10 copies/mL), with treatment to be offered in the third trimester. As more data are published in larger trials, this will inevitably lead to development of perinatal

treatment protocols in the United States. HBV-targeted maternal antiviral therapy in the third trimester of pregnancy should be considered to reduce transmission in cases where maternal viral load is >6-8 log 10 copies/mL. In pregnant women with HBV infection, we suggest HBV viral load testing in the third trimester (grade 2B). **In pregnant women with HBV infection and viral load >6-8 log 10 copies/mL, HBV-targeted maternal antiviral therapy should be considered for the purpose of decreasing the risk of intrauterine fetal infection (GRADE 2B). In pregnant women with HBV infection who are candidates for maternal antiviral therapy, we suggest tenofovir as a first-line agent (GRADE 2B).**

What other issues need to be considered in a pregnant woman diagnosed as a chronic HBV carrier?

Identification of a pregnant woman as chronically HBV infected also presents an important opportunity to counsel her regarding risks to other family and household members. HBV is most easily transmitted via sexual exposure or blood exposure but can also be transmitted through casual shared use of household items such as eating utensils and toothbrushes, as well as through personal contact such as kissing or routine childcare. Therefore, family and household members should be evaluated for HBV status and referred for vaccination if found to be uninfected and nonimmune. The pregnant woman herself should also be assessed for immunity status for hepatitis A and offered vaccination if not immune, since coinfection with another viral hepatitis results in compounded morbidity. The woman should also be counseled regarding exposures to potentially hepatotoxic medications, even those available over the counter, such as acetaminophen, and to avoid the use of alcohol even when not pregnant.

The majority of pregnant women diagnosed with chronic HBV infection will be asymptomatic and identified through routine screening with initial prenatal laboratory tests. To aid in counseling regarding risks and potential

management options as outlined above, baseline LFTs should also be drawn when a positive HBsAg test result is obtained, along with a baseline quantitative HBV-DNA level. Consideration should also be given to referral to a maternal-fetal medicine subspecialist or an infectious diseases specialist or hepatologist with experience managing hepatitis B to coordinate care and surveillance for the woman during and after pregnancy. If the baseline HBV DNA polymerase chain reaction testing is negative, it may be repeated in the third trimester, since this is usually the time when consideration is given to beginning antiviral treatment in women with high viral loads. In consideration of cost, baseline HBV-DNA testing during pregnancy can be deferred until the third trimester, especially if the initial LFT results are normal or results prior to pregnancy are available. Even if the maternal viral load is low and antiviral therapy during pregnancy is not recommended, the newborn should still receive standard prophylaxis with HBIG and HBV vaccine within 12 hours of birth, and ongoing surveillance of the woman's hepatic function after pregnancy is indicated. ∎

REFERENCES

1. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Philadelphia (PA): Churchill Livingstone Elsevier; 2010.
2. Kubo A, Shlager L, Marks AR, et al. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med 2014;160: 828-35.
3. Din ES, Wasley A, Jacques-Carroll L, Sirotkin B, Wang S. Estimating the number of births to hepatitis B virus-infected women in 22 states, 2006. Pediatr Infect Dis J 2011;30: 575-9.
4. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national perinatal hepatitis B prevention program, 1994-2008. Pediatrics 2012;129:609-16.
5. Lin K, Vickery J. Screening for hepatitis B virus infection in pregnant women: evidence for the US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009;150:874-6.
6. American College of Obstetricians and Gynecologists. Viral hepatitis in pregnancy. ACOG Practice bulletin no. 86. Obstet Gynecol 2007;110:941-55.

7. Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int 2010;30:275-83.

8. Hieber JP, Dalton D, Shorey J, Combes B. Hepatitis and pregnancy. J Pediatr 1977;91: 545-9.

9. Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009;29(Suppl): 133-9.

10. Lao TT, Tse KY, Chan LY, Tam KF, Ho LF. HBsAg carrier status and the association between gestational diabetes with increased serum ferritin concentration in Chinese women. Diabetes Care 2003;26:3011-6.

11. Lao TT, Chan BC, Leung WC, Ho LF, Tse KY. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol 2007;47:46-50.

12. Lobstein S, Faber R, Tillmann HL. Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. Digestion 2011;83:76-82.

13. Connell LE, Salihu HM, Salemi JL, August EM, Weldeselasse H, Mbah AK. Maternal hepatitis B and hepatitis C carrier status and perinatal outcomes. Liver Int 2011;31: 1163-70.

14. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM Jr, Janssen RS, Ward JW. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33.

15. Yang J, Zeng XM, Men YL, Zhao LS. Elective cesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus—a systematic review. Virol J 2008;5:100.

16. Gartner LM, Morton J, Lawrence RA, et al. American Academy of Pediatrics Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506.

17. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99: 1049-52.

18. de Martino M, Appendino C, Resti M, Rossi ME, Muccioli AT, Vierucci A. Should hepatitis B surface antigen positive mothers breast feed? Arch Dis Child 1985;60:972-4.

19. Ko TM, Tseng LH, Chang MH, et al. Amniocentesis in mothers who are hepatitis B virus carriers does not expose the infant to an increased risk of hepatitis B virus infection. Arch Gynecol Obstet 1994;255:25-30.

20. Chen LZ, Zhou WQ, Zhao SS, Liu ZY, Wen SW. A nested case-control study of maternal-neonatal transmission of hepatitis B virus in a Chinese population. World J Gastroenterol 2011;17:3640-4.

21. Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr 2007;166:813-8.

22. Gagnon A, Davies G, Wilson RD; Genetics Committee; Wilson RD, Audibert F, Brock JA, et al; Executive and Council of the Society of Obstetricians and Gynecologists of Canada. Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections. J Obstet Gynaecol Can 2014;36:648-55.

23. Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001;184:1514-8.

24. Yi W, Pan CQ, Hao J, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014;60:523-9.

25. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3:135-41.

26. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2: 1099-102.

27. Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8.

28. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.

29. Hwang SJ, Lee SD, Lu RH, et al. Comparison of three different hybridization assays in the quantitative measurement of serum hepatitis B virus DNA. J Virol Methods 1996;62:123-9.

30. Chen CJ, Yang HI, Su J, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.

31. Iloeje UH, Yang HI, Jen CL, et al; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus Study Group. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007;5:921-31.

32. Liaw YF, Sung JJ, Chow WC, et al; Cirrhosis Asian Lamivudine Multicenter Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.

33. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.

34. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.

35. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014;59: 434-42.

36. Corsa AC, Liu Y, Flaherty JF, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol 2014;12:2106-12.

37. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994;170:1418-23.

38. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-30.

39. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicenter, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103.

40. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190: 489-92.

41. Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012;10: 452-9.

42. Zhu Q, Yu G, Yu H, et al. A randomized control trial on interruption of HBV transmission in uterus. Chin Med J (Engl) 2003;116:685-7.

43. Yue Y, Yang X, Zhang S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: efficacy and mechanism. Chin Med J (Engl) 1999;112: 37-9.

44. Li XM, Shi MF, Yang YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004;10:3215-7.

45. Yuan J, Lin J, Xu A, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-center randomized study. J Viral Hepat 2006;13: 597-604.

46. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunization in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006;332:328-36.

47. Brown RS Jr, Verna EC, Pereira MR, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012;57:953-9.

48. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010;116:147-59.

49. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil

fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61:502-7.

50. Wu Q, Huang H, Sun X, et al. Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. Clin Gastroenterol Hepatol 2015;13: 1170-6.

51. Dunkelberg JC, Berkley EM, Thiel KW, Leslie KK. Hepatitis B and C in pregnancy: a review and recommendations for care. J Perinatol 2014;34:882-91.

52. Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e

antigen or viral load. Obstet Gynecol 2014;123: 929-37.

53. Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. Am J Obstet Gynecol 2012;207:231.e1-7.

54. Pirillo MF, Scarcella P, Andreotti M, et al. Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding. J Viral Hepat 2015;22:289-96.

55. Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a

review of the evidence. Clin Infect Dis 2015;60:275-8.

56. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.

57. National Institute for Health and Care Excellence. Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults. NICE guidelines [CG165]. Available at: https://www.nice.org.uk/guidance/cg165/resources/guidance-hepatitis-b-chronic-pdf. Accessed Aug. 4, 2015.

58. Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014;60:448-51.